tiprankstipranks
Legend Biotech Corporation (DE:9LB)
NASDAQ:9LB
Germany Market
9LB
Legend Biotech
RESEARCH TOOLSreports

Legend Biotech (9LB) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

9LB Analyst Ratings

Strong Buy
9Ratings
Strong Buy
8 Buy
1 Hold
0 Sell
Based on 9 analysts giving stock ratings to
Legend
Biotech
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

9LB Stock 12 Month Forecast

Average Price Target

€49.62
▲(175.66% Upside)
Based on 9 Wall Street analysts offering 12 month price targets for Legend Biotech in the last 3 months. The average price target is €49.62 with a high forecast of €68.98 and a low forecast of €25.00. The average price target represents a 175.66% change from the last price of €18.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"€13","27":"€27","41":"€41","55":"€55","69":"€69"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":68.9783616,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€68.98</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":49.618434777599994,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€49.62</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25.00465608,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€25.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,27,41,55,69],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.8,25.42910473846154,29.05820947692308,32.68731421538462,36.31641895384615,39.94552369230769,43.57462843076923,47.20373316923077,50.83283790769231,54.461942646153844,58.09104738461538,61.72015212307693,65.34925686153846,{"y":68.9783616,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.8,23.939879598276924,26.079759196553844,28.219638794830768,30.35951839310769,32.49939799138461,34.63927758966154,36.77915718793846,38.919036786215386,41.058916384492306,43.19879598276923,45.33867558104615,47.478555179323074,{"y":49.618434777599994,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.8,22.046512006153847,22.293024012307693,22.53953601846154,22.786048024615386,23.032560030769233,23.279072036923075,23.525584043076922,23.77209604923077,24.018608055384615,24.26512006153846,24.511632067692307,24.758144073846154,{"y":25.00465608,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":25.4,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.8,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.6,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.5,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.4,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.6,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.3,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.8,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€68.98Average Price Target€49.62Lowest Price Target€25.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on DE:9LB
Etzer Darout
Barclays
Barclays
€68.98
Buy
283.21%
Upside
Reiterated
06/15/26
Barclays Keeps Their Buy Rating on Legend Biotech (LEGN)
Piper Sandler Analyst forecast on DE:9LB
Edward Tenthoff
Piper Sandler
Piper Sandler
€55.18
Buy
206.57%
Upside
Reiterated
06/15/26
Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN), Ascendis Pharma (NASDAQ: ASND) and Lyell Immunopharma (NASDAQ: LYEL)
Oppenheimer Analyst forecast on DE:9LB
Kostas Biliouris
Oppenheimer
Oppenheimer
€64.67
Buy
259.26%
Upside
Reiterated
06/15/26
Legend Biotech (LEGN) Receives a Buy from Oppenheimer
UBS Analyst forecast on DE:9LB
Ashwani Verma
UBS
UBS
€26.73→€42.25
Buy
134.72%
Upside
Assigned
06/04/26
Legend Biotech price target raised to $49 from $31 at UBSLegend Biotech price target raised to $49 from $31 at UBS
H.C. Wainwright Analyst forecast on DE:9LB
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
€43.11→€56.04
Buy
211.36%
Upside
Reiterated
06/03/26
Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN), Tempus AI, Inc. Class A (NASDAQ: TEM) and Mirum Pharmaceuticals (NASDAQ: MIRM)
RBC Capital Analyst forecast on DE:9LB
Leonid Timashev
RBC Capital
RBC Capital
€55.18
Buy
206.57%
Upside
Reiterated
06/01/26
RBC Capital Remains a Buy on Legend Biotech (LEGN)
TD Cowen Analyst forecast on DE:9LB
Yaron Werber
TD Cowen
TD Cowen
€18.11→€25
Hold
38.91%
Upside
Assigned
05/13/26
Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN), Tvardi Therapeutics (NASDAQ: TVRD) and Organigram Global (NASDAQ: OGI)
Morgan Stanley Analyst forecast on DE:9LB
Terence Flynn
Morgan Stanley
Morgan Stanley
€42.25→€41.39
Buy
129.93%
Upside
Reiterated
05/13/26
Legend Biotech price target lowered to $48 from $49 at Morgan StanleyLegend Biotech price target lowered to $48 from $49 at Morgan Stanley
Goldman Sachs Analyst forecast on DE:9LB
Ziyi Chen
Goldman Sachs
Goldman Sachs
€38.59→€37.87
Buy
110.38%
Upside
Reiterated
05/12/26
Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN), Ovid Therapeutics (NASDAQ: OVID) and Arvinas Holding Company (NASDAQ: ARVN)
Truist Financial Analyst forecast on DE:9LB
Asthika Goonewardene
Truist Financial
Truist Financial
€60.36
Buy
235.31%
Upside
Reiterated
03/13/26
Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN) and Medtronic (NYSE: MDT)
Deutsche Bank Analyst forecast on DE:9LB
James Shin
Deutsche Bank
Deutsche Bank
€51.73
Buy
187.41%
Upside
Reiterated
03/09/26
Analysts Are Bullish on These Healthcare Stocks: Legend Biotech (LEGN), Lantheus (LNTH)
Rothschild & Co Redburn Analyst forecast on DE:9LB
Qize Ding
Rothschild & Co Redburn
Rothschild & Co Redburn
€71.57→€20.69
Hold
14.96%
Upside
Downgraded
02/12/26
Legend Biotech downgraded to Neutral from Buy at Rothschild & Co RedburnLegend Biotech downgraded to Neutral from Buy at Rothschild & Co Redburn
Cantor Fitzgerald Analyst forecast on DE:9LB
Eric Schmidt FCA
Cantor Fitzgerald
Cantor Fitzgerald
€64.67→€63.8
Buy
254.47%
Upside
Reiterated
12/17/25
Legend Biotech price target lowered to $74 from $75 at Cantor FitzgeraldLegend Biotech price target lowered to $74 from $75 at Cantor Fitzgerald
William Blair Analyst forecast on DE:9LB
Sami Corwin
William Blair
William Blair
―
Hold
―
Reiterated
11/12/25
Legend Biotech's Strategic Growth and Risks: Analyst Assigns Hold Rating
J.P. Morgan Analyst forecast on DE:9LB
Jessica Fye
J.P. Morgan
J.P. Morgan
€67.25→€65.53
Buy
264.05%
Upside
Reiterated
10/09/25
J.P. Morgan Keeps Their Buy Rating on Legend Biotech (LEGN)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on DE:9LB
Etzer Darout
Barclays
Barclays
€68.98
Buy
283.21%
Upside
Reiterated
06/15/26
Barclays Keeps Their Buy Rating on Legend Biotech (LEGN)
Piper Sandler Analyst forecast on DE:9LB
Edward Tenthoff
Piper Sandler
Piper Sandler
€55.18
Buy
206.57%
Upside
Reiterated
06/15/26
Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN), Ascendis Pharma (NASDAQ: ASND) and Lyell Immunopharma (NASDAQ: LYEL)
Oppenheimer Analyst forecast on DE:9LB
Kostas Biliouris
Oppenheimer
Oppenheimer
€64.67
Buy
259.26%
Upside
Reiterated
06/15/26
Legend Biotech (LEGN) Receives a Buy from Oppenheimer
UBS Analyst forecast on DE:9LB
Ashwani Verma
UBS
UBS
€26.73→€42.25
Buy
134.72%
Upside
Assigned
06/04/26
Legend Biotech price target raised to $49 from $31 at UBSLegend Biotech price target raised to $49 from $31 at UBS
H.C. Wainwright Analyst forecast on DE:9LB
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
€43.11→€56.04
Buy
211.36%
Upside
Reiterated
06/03/26
Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN), Tempus AI, Inc. Class A (NASDAQ: TEM) and Mirum Pharmaceuticals (NASDAQ: MIRM)
RBC Capital Analyst forecast on DE:9LB
Leonid Timashev
RBC Capital
RBC Capital
€55.18
Buy
206.57%
Upside
Reiterated
06/01/26
RBC Capital Remains a Buy on Legend Biotech (LEGN)
TD Cowen Analyst forecast on DE:9LB
Yaron Werber
TD Cowen
TD Cowen
€18.11→€25
Hold
38.91%
Upside
Assigned
05/13/26
Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN), Tvardi Therapeutics (NASDAQ: TVRD) and Organigram Global (NASDAQ: OGI)
Morgan Stanley Analyst forecast on DE:9LB
Terence Flynn
Morgan Stanley
Morgan Stanley
€42.25→€41.39
Buy
129.93%
Upside
Reiterated
05/13/26
Legend Biotech price target lowered to $48 from $49 at Morgan StanleyLegend Biotech price target lowered to $48 from $49 at Morgan Stanley
Goldman Sachs Analyst forecast on DE:9LB
Ziyi Chen
Goldman Sachs
Goldman Sachs
€38.59→€37.87
Buy
110.38%
Upside
Reiterated
05/12/26
Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN), Ovid Therapeutics (NASDAQ: OVID) and Arvinas Holding Company (NASDAQ: ARVN)
Truist Financial Analyst forecast on DE:9LB
Asthika Goonewardene
Truist Financial
Truist Financial
€60.36
Buy
235.31%
Upside
Reiterated
03/13/26
Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN) and Medtronic (NYSE: MDT)
Deutsche Bank Analyst forecast on DE:9LB
James Shin
Deutsche Bank
Deutsche Bank
€51.73
Buy
187.41%
Upside
Reiterated
03/09/26
Analysts Are Bullish on These Healthcare Stocks: Legend Biotech (LEGN), Lantheus (LNTH)
Rothschild & Co Redburn Analyst forecast on DE:9LB
Qize Ding
Rothschild & Co Redburn
Rothschild & Co Redburn
€71.57→€20.69
Hold
14.96%
Upside
Downgraded
02/12/26
Legend Biotech downgraded to Neutral from Buy at Rothschild & Co RedburnLegend Biotech downgraded to Neutral from Buy at Rothschild & Co Redburn
Cantor Fitzgerald Analyst forecast on DE:9LB
Eric Schmidt FCA
Cantor Fitzgerald
Cantor Fitzgerald
€64.67→€63.8
Buy
254.47%
Upside
Reiterated
12/17/25
Legend Biotech price target lowered to $74 from $75 at Cantor FitzgeraldLegend Biotech price target lowered to $74 from $75 at Cantor Fitzgerald
William Blair Analyst forecast on DE:9LB
Sami Corwin
William Blair
William Blair
―
Hold
―
Reiterated
11/12/25
Legend Biotech's Strategic Growth and Risks: Analyst Assigns Hold Rating
J.P. Morgan Analyst forecast on DE:9LB
Jessica Fye
J.P. Morgan
J.P. Morgan
€67.25→€65.53
Buy
264.05%
Upside
Reiterated
10/09/25
J.P. Morgan Keeps Their Buy Rating on Legend Biotech (LEGN)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Legend Biotech

3 Months
Edward TenthoffPiper Sandler
Success Rate
8/16 ratings generated profit
50%
Average Return
+9.35%
Copying Edward Tenthoff's trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +9.35% per trade.
1 Year
Edward TenthoffPiper Sandler
Success Rate
8/16 ratings generated profit
50%
Average Return
+0.18%
Copying Edward Tenthoff's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +0.18% per trade.
2 Years
Justin ZelinBTIG
Success Rate
12/32 ratings generated profit
38%
Average Return
-4.58%
Copying Justin Zelin's trades and holding each position for 2 Years would result in 37.50% of your transactions generating a profit, with an average return of -4.58% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

9LB Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
16
19
20
28
25
Buy
0
0
0
0
1
Hold
2
3
2
2
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
18
22
22
30
27
In the current month, 9LB has received 26 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 9LB average Analyst price target in the past 3 months is 49.62.
Each month's total comprises the sum of three months' worth of ratings.

9LB Financial Forecast

9LB Earnings Forecast

Next quarter’s earnings estimate for 9LB is €0.07 with a range of -€0.06 to €0.18. The previous quarter’s EPS was -€0.13. 9LB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 9LB has Performed in-line its overall industry.
Next quarter’s earnings estimate for 9LB is €0.07 with a range of -€0.06 to €0.18. The previous quarter’s EPS was -€0.13. 9LB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 9LB has Performed in-line its overall industry.

9LB Sales Forecast

Next quarter’s sales forecast for 9LB is €313.61M with a range of €293.04M to €334.03M. The previous quarter’s sales results were €264.36M. 9LB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 9LB has Performed in-line its overall industry.
Next quarter’s sales forecast for 9LB is €313.61M with a range of €293.04M to €334.03M. The previous quarter’s sales results were €264.36M. 9LB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 9LB has Performed in-line its overall industry.

9LB Stock Forecast FAQ

What is DE:9LB’s average 12-month price target, according to analysts?
Based on analyst ratings, Legend Biotech Corporation’s 12-month average price target is 49.62.
    What is DE:9LB’s upside potential, based on the analysts’ average price target?
    Legend Biotech Corporation has 175.66% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Legend Biotech Corporation a Buy, Sell or Hold?
          Legend Biotech Corporation has a consensus rating of Strong Buy, which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Legend Biotech Corporation’s share price target?
            The average share price target for Legend Biotech Corporation is 49.62. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €68.98 ,and the lowest forecast is €25.00. The average share price target represents 175.66% Increase from the current price of €18.
              What do analysts say about Legend Biotech Corporation?
              Legend Biotech Corporation’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
                How can I buy shares of Legend Biotech Corporation?
                To buy shares of DE:9LB, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.